NDAINJECTIONINJECTABLE
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DURACLON (clonidine hydrochloride) by Viatris (2) is mechanism of action epidurally administered clonidine produces dose-dependent analgesia not antagonized by opiate antagonists. First approved in 1996.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURACLON is an epidurally administered clonidine hydrochloride injection approved in 1996 for pain management. It works as an alpha-2-adrenergic agonist that produces dose-dependent analgesia by preventing pain signal transmission at presynaptic and postjunctional alpha-2-adrenoceptors in the spinal cord. The analgesia is localized to body regions innervated by spinal segments where therapeutic concentrations are present.
LOE Approaching
Product approaching loss of exclusivity with limited commercial growth opportunities, likely requiring defensive strategies and cost-containment focus within a lean team.
Mechanism of Action
Mechanism of Action Epidurally administered clonidine produces dose-dependent analgesia not antagonized by opiate antagonists. The analgesia is limited to the body regions innervated by the spinal segments where analgesic concentrations of clonidine are present. Clonidine is thought to produce…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DURACLON offers limited career growth as a near-LOE small-molecule injectable with minimal linked job opportunities and no active clinical pipeline. This role is best suited for professionals seeking to manage a mature specialty product, develop cost-containment strategies, or gain experience in post-LOE portfolio management within Viatris' pain management franchise.
Brand Manager
Worked on DURACLON at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.